Outcome of the Financials in the Board Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Kimia Biosciences approved the audited financial results for Q4 and FY ended March 31, 2025, with an unmodified audit opinion. The company posted a profit after tax of Rs. 961.24 lakhs in FY25, compared to a loss of Rs. 530.87 lakhs in FY24, driven by a strong swing in pre-tax profit from a Rs. 718.37 lakh loss to a Rs. 1,363.42 lakh profit. Revenue from operations grew about 13.4% to Rs. 11,892.08 lakhs (from Rs. 10,487.65 lakhs), while total expenses fell to Rs. 10,660.69 lakhs from Rs. 11,370.20 lakhs, reflecting better operating efficiency. Total equity strengthened sharply from Rs. 33.10 lakhs to Rs. 996.61 lakhs. The company also began redeeming its preference shares, and non-current borrowings were cut nearly in half.
This is a clear turnaround story — shareholders should view the return to profitability and improved equity base as positive, though the stock still carries elevated debt (roughly Rs. 32.6 crore in borrowings against ~Rs. 10 crore of equity, a D/E near 3.3x), which remains a watchpoint.